Skip to search formSkip to main contentSkip to account menu

PDGFRB NP_002600.1:p.T681I

Known as: Beta Platelet-Derived Growth Factor Receptor Thr681Ile, Platelet-Derived Growth Factor Receptor 1 Thr681Ile, Platelet-Derived Growth Factor Receptor Beta Thr681Ile 
A change in the amino acid residue at position 681 in the platelet-derived growth factor receptor beta protein where threonine has been replaced by… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Co‐occurrence of a novel PDGFRB variant and likely pathogenic variant in CASR in an individual with extensive intracranial calcifications and hypocalcaemia
This case report describes an individual with brain calcifications, cognitive decline, motor dysfunction, and hypocalcaemia… 
2017
2017
[Sporadic infantile myofibromatosis: Mutations with PDGFRB gain-of-function].
2017
2017
MYELOPROLIFERATIVE NEOPLASMS Myeloid neoplasms with eosinophilia
Molecular diagnostics hasgenerated substantial dividends in dissecting the genetic basis of myeloid neoplasms with eosinophilia… 
2012
2012
Cytogenetic changes in renal cell carcinoma: Basis for sensitivity and resistance to everolimus.
403 Background: The mTOR inhibitors have improved outcomes for pts with metastatic renal cell carcinoma (mRCC) but the duration… 
2012
2012
Cytogenetic changes in renal cell carcinoma: Basis for sensitivity and resistance to everolimus.
403 Background: The mTOR inhibitors have improved outcomes for pts with metastatic renal cell carcinoma (mRCC) but the duration… 
2012
2012
Preclinical Development Sensitivity ofSelectedHumanTumorModels toPF-04217903 , a Novel Selective c-Met Kinase Inhibitor
The c-Met pathway has been implicated in a variety of human cancers for its critical role in tumor growth, invasion… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)